Vaxine Announces Major Progress In Trial Of World's First Swine Flu Vaccine

< BACK TO HEALTH starstarstarstarstar   Community - Health Press Release
12th August 2009, 11:00am - Views: 665





Community Health Vaxine Pty Ltd 1 image


Media enquiries: Prof. Nikolai

Petrovsky, nikolai.petrovsky@flinders.edu.au

cell phone:




VAXINE ANNOUNCES

MAJOR PROGRESS IN TRIAL OF WORLD’S FIRST

SWINE FLU VACCINE 

Vaxine announced that its investigators at Flinders Medical Centre in Adelaide have

started giving trial subjects their critical second swine flu vaccine booster. 

“We are excited to continue to lead the world in clinical tests of swine flu vaccine,” said

Professor Nikolai Petrovsky, Vaxine Research Director.  “We will soon know outcomes of

the first immunisation from blood results but are working on the assumption that two

immunisations will be required.”

For these trials, Vaxine is using its proprietary Advax ™ sugar-based vaccine enhancer

with influenza antigen from US partner, Protein Sciences Corporation. The trial will provide

the world’s first insight into what dose and how many boosters are required for protection. 

“The only current benchmark to what might be needed is Sanofi’s H5N1 vaccine that

required 2x90 microgram doses to be effective”

said Prof. Petrovsky. “This is six times

higher than what most vaccine manufacturers

are planning for their swine flu vaccines.

Vaxine’s soon to be released trial data is going to be critical to help government authorities

identify the optimum vaccine dose. If the swine flu vaccine turns out anything like the H5N1

vaccine, then the global swine flu vaccine shortfall is going to be immense, with supply being

only one sixth of current projections.”

Vaxine with funding assistance from AusIndustry and the US National Institute of Health

has developed a novel vaccine enhancement technology called Advax™ that when co-

administered boosts vaccine effectiveness while reducing dose. Using this technology, limited

vaccine can be stretched further, enabling swine flu vaccine supplies to better meet global

meets.

Vaxine’s sugar-based Advax™ enhancement

technology has little in common with

vaccine adjuvants that have received considerable negative press because of safety and

side-effect concerns. Clinical studies of Advax™ confirm its unique ability to enhance

vaccine effectiveness without side-effects. Vaxine is currently establishing partnerships with

vaccine manufacturers around the world to make Advax™ technology globally available,

thereby providing a safe and effective alternative to current vaccine ingredients such as

aluminium and mercury.


About Vaxine Pty Ltd

Established in 2002, Vaxine is an Australian-based biotechnology company specialising in development of

novel vaccine technologies. Lead products in late-stage development include vaccines for seasonal and

pandemic influenza, Japanese encephalitis, hepatitis B, and bee sting allergy plus the

Advax™ vaccine

enhancement technology. More information on Vaxine and its projects can be found at http://vaxine.com.au







news articles logo NEWS ARTICLES
Contact News Articles |Remove this article